Financial StabilitySight maintains a solid $120 million cash position, enabling flexibility for ongoing product launches, market access efforts, and further R&D investments.
Product PerformanceTearCare is preferred for its superior patient comfort and long-lasting benefits, indicating high patient satisfaction and clinical effectiveness.
Revenue PerformanceSGHT's first-quarter sales of $17.5 million were $1 million above estimates, showcasing better-than-expected performance.